<SEC-DOCUMENT>0001639691-18-000002.txt : 20180116
<SEC-HEADER>0001639691-18-000002.hdr.sgml : 20180116
<ACCEPTANCE-DATETIME>20180116114843
ACCESSION NUMBER:		0001639691-18-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180116
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180116
DATE AS OF CHANGE:		20180116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LivaNova PLC
		CENTRAL INDEX KEY:			0001639691
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				981268150
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37599
		FILM NUMBER:		18527912

	BUSINESS ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG
		BUSINESS PHONE:		4402033250662

	MAIL ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Plc
		DATE OF NAME CHANGE:	20150420

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Ltd
		DATE OF NAME CHANGE:	20150415
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>livanovaform8-k_imtheraacq.htm
<DESCRIPTION>LIVANOVA FORM 8-K (IMTHERA ACQUISITION)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF511D620ADEB7D324FB7FBCE575A5C5F"></a></div><div></div><div><br></div><div style="line-height:120%;-sec-extract:summary;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported): January 16, 2018</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;"><img src="livanovaform8kimthera_image1.jpg" alt="livanovaform8kimthera_image1.jpg" style="height:54px;width:172px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LivaNova PLC</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">England and Wales</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-37599</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98-1268150</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20 Eastbourne Terrace</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">London, W2 6LG</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">United Kingdom</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(44) 203 325 0660</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:67%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:67%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;-sec-extract:summary;"><hr></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFB2FF6563E8279CF762EFBCE578AF168"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Item 8.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Other Events</font></div><div style="line-height:132%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 5, 2017, LivaNova PLC ("LivaNova") announced that it had entered into an agreement to acquire the remaining outstanding interests of ImThera Medical, Inc.  The transaction closed on January 16, 2018.</font></div><div style="line-height:132%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A copy of LivaNova's press release announcing its entering into an agreement to acquire the remaining outstanding interests of ImThera Medical, Inc. is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</font></div><div style="line-height:152%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Financial Statements and Exhibits</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit_991.htm"><font style="font-family:inherit;font-size:10pt;">Press Release issued by LivaNova PLC dated December 5, 2017</font></a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s8F47685FD4BCA25A0E62FBCE57AC4950"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LivaNova PLC</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  January 16, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;By:</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Catherine Moroz</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:  Catherine Moroz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:    Company Secretary</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_991.htm
<DESCRIPTION>LIVANOVA PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s847A5AC263DF1BA6640AFBD78A90509A"></a></div><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 99.1</font></div><div style="line-height:138%;text-align:left;"><img src="exhibit991image1.jpg" alt="exhibit991image1.jpg" style="height:62px;width:214px;"></div><div style="line-height:138%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">NEWS RELEASE</font></div><div style="line-height:120%;text-align:left;"><hr></div><div style="line-height:138%;padding-top:16px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;color:#ff5c39;font-weight:bold;">LivaNova to Acquire ImThera Medical, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;font-style:italic;">Company will enter Obstructive Sleep Apnea space, enhancing its portfolio of Neuromodulation treatments and therapies</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">London, Dec. 5, 2017 &#8211;</font><font style="font-family:Arial;font-size:11pt;">&#32;LivaNova PLC (NASDAQ:LIVN) (&#8220;LivaNova&#8221; or the &#8220;Company&#8221;), a market-leading medical technology company, today announced it has entered into an agreement to acquire the remaining outstanding interests in ImThera Medical, Inc. (&#8220;ImThera&#8221;). Headquartered in San Diego, Calif., ImThera is a privately held company focused on neurostimulation for the treatment of obstructive sleep apnea (&#8220;OSA&#8221;). ImThera manufactures an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. </font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;The ImThera device is highly aligned with our existing Neuromodulation business, and we are extremely excited about the opportunity to optimize the technology and fold it into our universal platform. In the near term, we will focus on expanding ImThera&#8217;s current commercial presence in the European market, while advancing enrollment in a U.S. Food and Drug Administration (FDA) pivotal trial,&#8221; said Damien McDonald, LivaNova&#8217;s Chief Executive Officer. &#8220;The OSA market is large and growing, with many unmet needs. With our strong commercial capabilities and robust manufacturing, we look forward to bringing this innovative technology to the large patient population that has been unsuccessful with other treatments, allowing them to improve their quality of life.&#8221;  </font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Patients with OSA can experience impaired daytime functionality, along with severe comorbidities such as heart failure and stroke. ImThera&#8217;s implantable device received CE Mark in 2012 and is indicated for patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (&#8220;CPAP&#8221;) therapy. For these patients, the device is designed to reduce or eliminate sleep apnea, as demonstrated through clinical studies and its initial commercial use in Europe. Enrollment in a pivotal study is currently under way with the FDA to obtain premarket approval for the OSA implant.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;Adding ImThera and its obstructive sleep apnea device to our portfolio will strengthen our position as a leader in the field of neuromodulation,&#8221; said Jason Richey, LivaNova's President of&#160;North America&#160;and General Manager of the Neuromodulation business. </font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LivaNova has been an investor in ImThera since 2011 and has agreed to pay up to approximately $225 million to acquire the remaining outstanding interests of ImThera. Up-front costs are approximately $78 million with the balance paid on a schedule driven by regulatory and sales milestones. The deal is projected to be near-term accretive and is expected to close in early 2018 (subject to approvals and other customary closing conditions).  </font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;ImThera Medical shares LivaNova&#8217;s mission to help patients live longer, better lives. We are proud of the accomplishments we have made in developing an effective CPAP alternative for individuals suffering from OSA. This acquisition will benefit healthcare providers, shareholders and most of all, the patients who are at the heart of everything we do,&#8221; said Marcelo Lima, ImThera&#8217;s Founder, President and Chief Executive Officer. &#8220;This is the culmination of several years of hard work by our team of dedicated professionals. We welcome the opportunity to become part of the LivaNova family and look forward to the continued evolution of our product.&#8221; </font></div><div style="line-height:180%;padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">About ImThera Medical, Inc.</font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ImThera Medical is a global leader in neurostimulation for the treatment of obstructive sleep apnea. Headquartered in San Diego, ImThera was founded to improve the lives of patients suffering from the debilitating effects of OSA. ImThera&#8217;s sleep therapy product is comprised of an implanted small generator and multi-channel electrode lead, along with an external handheld remote control that can start, stop or pause therapy. ImThera collaborates with the world&#8217;s top scientists and medical experts in sleep medicine, and its product is commercially available in several countries outside the United States. </font></div><div style="line-height:180%;padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">About LivaNova</font></div><div style="line-height:216%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova&#8217;s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:216%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LivaNova&#160;operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy),&#160;Houston&#160;(U.S.A.) and Clamart (France), respectively.</font></div><div style="line-height:180%;padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">Safe Harbor Statement </font></div><div style="line-height:216%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company&#8217;s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," &#8220;could,&#8221; &#8220;seek,&#8221; &#8220;guidance,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but are inherently uncertain. As a result, the Company&#8217;s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company&#8217;s control. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning closing of the proposed acquisition of ImThera, entry into the OSA space, developing the ImThera device as an important growth platform, investing in the clinical studies, regulatory approvals, product enhancements and other steps needed to launch this device commercially in new markets, developing ImThera as a positive addition to the Company&#8217;s neuromodulation portfolio, offering patients the most advanced OSA therapy, offering a significant new therapy to patients with OSA, adding clinical study sites for ImThera&#8217;s implantable device, bringing a superior technology to market and anticipating that this transaction will meet all LivaNova </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:216%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">long-term financial metrics and internal standards. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company&#8217;s business, including those described in the &#8220;Risk Factors&#8221; section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof.</font></div><div style="line-height:216%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">All information in this press release is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">For more information, please visit www.livanova.com.</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">LivaNova PLC Investor Relations and Media</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Karen King, </font><font style="font-family:Arial;font-size:11pt;">+1 (281) 228-7262</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Vice President, Investor Relations &amp; Corporate Communications</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Deanna Wilke,</font><font style="font-family:Arial;font-size:11pt;">&#32;+1 (281) 727-2764</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Corporate External Communications Manager</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Corporate.Communications@LivaNova.com</font></a></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit991image1.jpg
<DESCRIPTION>LIVANOVA LOGO
<TEXT>
begin 644 exhibit991image1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "/ >T# 2(  A$! Q$!_\0
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M;K_OZW^-']OWQ_Y?;K_O\W^-?TR?\/ _V8_^BK?"3_P;VG_Q5!_X*!?LQ?\
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M_P!XI_XE^9_+[7T1_P $EO\ E))\&_\ L8X?Y-7SO7T1_P $EO\ E))\&_\
ML8X?Y-7[5F'^Z5/\+_(_8L=_NM3_  O\C^FB[MX[NVDBE19(Y%*NC#<K \$$
M>E?S"_\ !2K]EB3]CK]L_P ;>"XX6AT>*\-_HQ(X>QG_ 'D(![[ 3&3_ 'HV
MK^GZORP_X.:?V4#XJ^$_A7XO:;;;KSPM<?V+J[(O)LYVS"['T2;*_P#;Q[5^
M9\)8_P!AC?92^&>GSZ?Y?,_.>%<=[#&>REM/3Y]/\OF?BU7]"7_!O_\ M/\
M_"_?V"-*T*]N/.UOX<W#:!.&;YS; ;[5L?W1$WEC_KB:_GMK[^_X-UOVG/\
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M_13^RQ^T9H?[6/P"\,_$#P[(K:;XCLUG\K=E[64$K+"_^U'(K(?=?2OYUO\
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M9&;>,J+9VCZ]7_D%:'A?PEJOC?68=-T73=0U?4+@[8K6RMWN)I3_ +**"Q_
M5VW[)G[-&N_M?_M!^&_A[X=VQW_B"Y\M[AUW1V4"@O+.P_NH@9L=\ =2*_I*
M_8X_84^'?[#WPVM=!\$Z+!!<>4JW^K3(K:AJD@'+RRXSR<D(,*N< "OI<[X@
MIY>E&W--]-M.[9]%G6?4\ E&W--]/+NS^<+Q#^PU\:O"6AMJ>J?"+XFZ;IRJ
M7:YN?#%[%%&/5F:/"_CBO+G1HG965E93@@C!!K^O(C=7P/\ \%@O^"0WA?\
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MC>))+24@?<%Q;L0?S@ _$5^(]=?"5O[-C;N[_?\ Y6.SA6W]G1MW?YGZB?\
M!KM\.+76OVA/B9XHFC62XT'0;:P@8_\ +/[5.S,1[XML9]"1WK]L!P*_#G_@
MV-^,=GX._:K\:>#[N989/&6@I/9AFQYT]I*6V =SY4LK?2,U^XU?$\6*2S*7
M-M96]+?YW/C.*E)9C+F[*WI;_.X4C\J:6H[F=+:VDDD98XXU+,S' 4#DDFOF
MSYP_ET_X*(?#VU^%?[=/Q9T&QC6*QL?%%]]GC486*-Y6D11]%8#\*\:KU/\
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M/,*/+_,ONZ_@=N1J3Q]+E[K_ (/X'X3T445^U'[$?N/_ ,10'P<_Z$7XD_\
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M^](K]?1?\ ]//,UA@L.W?WWI%?KZ(^V-,TZ#2-.M[2UB2"VM8UBBC086-%
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M "<_^,U^W]%'^MF8_P R^Y!_K5F/\R^Y'XY_LZ?\&X?Q0^#'[07@7QA?>.O
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MQ./LN>*^"%[."?Q6YM_/R/5/B/X[NOAG^Q==:Y8G;?:?X:B>W;_GG(8556_
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M\$FOB)J'B?X/:WH5],]Q'X9OEBM68YV12*6\L>P96(]-V*\@^'WP*T_X^?\
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MRNZ.& 8@/O&Y2 <J/3GJ?V?$\8:U_P %%M"\1>,K6UL]2\0Z;/J"06\JNEO
MUM*D2<$]%0=S[\YKY^G6]IBJ6BC-55S14+<MY-:S>KYNVWW'W=?!_5\LQ*<G
M.E+"ODJ2JIJ=H)VC16D5#ONN[N:__!7'X::%H/AW0_$5II=K;ZYK&IF.]O47
M][<*L&%#'V"J/P%?5'PA^!/A'X46OVKP[H&G:/<7]O&MQ);IM:8 9&?Q)->4
M_P#!3'X*ZE\8/@7#-I*QRWGAN[^WO$SA/,A\MEDP6(&1D-R>0#WP*D_8<_;2
MF_:<N]0T>[T./2;C0K&%VECN/-6Y;)1S@J-H^Z0,GJ>>.?IZ*P^'SNI&K%*5
M11<--VD^:SMH^^US\YQDL=CN#L//#3<H8>5155S;)RA[.\6[M=M&EY6/&?VE
M/@CX3T?]O[X=Z';:#I\.DZXD4U_:JG[NZ=YI@S,.Y.!^5?4WB_0]&_9=_9]\
M77GA/2;/28]/L+K4XX+=,1M<"' 8CG^XF?85X3_P43\*ZWX ^*G@OXN:7;P7
MUOX59(;N"24)C;*77W(;<RDKDC@XKU?]G;XV6G[;7P'\037VD-I-K>/<:/<6
MPG\[=$T*@L&VCDB0CIQBL\!&C1QV)PR2C5DVX:='%:IVVOT.C.ZF*Q>39=F4
MI.IAJ:4*OO7]]3;M*+=VW%JSMM;78^)OV8OB1X%\-:1J>I^-/A[X@\?Z[JMT
M[O>-:K<VZ(<9 #''F%BQ+$9Y&,8Y[K]C/Q5_PCG[;>WPEH/B+0/!GBF.6&2Q
MOH6Q;E86D'/(P)$(4DY 8BG>$OCCXR_X)I7VI>"];T2S\1Z+<7+WFF3I>B%B
M&P-PP&(#;1E64$-D@G//M?[%7C;XH?'GQGJGCCQ)J$.F^#KZ/R]/T:'RY$=A
M@!@>70*,DDD%F/3 Q7SV4T(RK4,/S-582O**II-6WYIW5T_G>ZT/NN*,9.&$
MQN.]G%X:M#EA-UVXSO;EY*5GRRCO:R2L];79YG_P56T"X\5?&3X8Z79L8[S4
MEDM8''\+O/$JG\R*^GOA!^R?X'^"4&FOHF@V$>IZ;$8AJ31 WDQ9=KLTG4[N
M>.@SP *\&_;ZLY)_VL_@?(JY6+5(2QST_P!-@K[!?[I^E?59;@Z4\SQ5:<4Y
M*4;-K;W4]/ZZ(_->(LTQ-/AS+,'2FXPE"HY)-J_OM:VW5KV3[L^'/VT_!E]\
M-_VN;7XA>)/"$GC?P))9I \(3S8K4B,H0PP0I#$N-XVMN/.1D>M?L?\ C3X+
MR^'M8O/ 0M=%:^N4FU&TOG,<\#$'8N'8C8/GVA"5&6^E<!^T)^T!\3/V1/CM
MJ&M:QY'BSP)X@'E6%H\R6XM@,D( H)5UR06*D.,9.0,>4?"W]C[7OVR=4\1>
M/(FT_P %Z3K%Z9;*VMVW(^<[@ N,;>.2!DL3@5X?UF5',9+"4^>HY2;A**4H
LZ?%&>W*^WR/LO[/AC<@I2S;$>QH1ITXQJTYMPG9Z0G1=GSQUNTEJKO8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>livanovaform8kimthera_image1.jpg
<DESCRIPTION>LIVANOVA LOGO
<TEXT>
begin 644 livanovaform8kimthera_image1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M:WD7FK$/NQMDA@/;H?QKTL-4<XZ]#TL-4<XZ]#U7X-_\D[TWZR_^C7KBQ/\
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MP:M+2VNCJM\+FYFA>*+9'\D#,"-^"<L1VZ?X1/%-M<J)GBFVK(UOA_\ #?\
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3 !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
